New Zealand markets closed

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.0000-0.0700 (-6.54%)
As of 01:51PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.0700
Bid1.0000 x 1000
Ask1.0100 x 1300
Day's range1.0000 - 1.0900
52-week range1.0000 - 9.5400
Avg. volume253,809
Market cap46.553M
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
EPS (TTM)-0.8910
Earnings date01 Aug 2022 - 05 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.38
  • GlobeNewswire

    Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

    Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CPI-818 (ITK inhibitor) Company to webcast its R&D Symposium today at 9:00 am ET / 6:00 am PT BURLINGAME, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-sta

  • Simply Wall St.

    We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

    Corvus to Host R & D Symposium on May 10BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are advancing our three clinical product candidates according to a clear strategy focused on the interaction of tumors with the immune system,” said Richard A. Miller, M.D., co-founder, pr